An aquirer will likely have many other parts. So the exposure for Neurens assets would be highly diluted if a current shareholder invested in the aquirer.
Thus it would`t be effective. IMO
Best to get the maximum possible when/if TO occurs. Not good enough offer, send `em packing.
It will really depend if there is more than 1 suitor.
- Forums
- ASX - By Stock
- NEU
- Ann: 2023 Annual Report to shareholders
NEU
neuren pharmaceuticals limited
Add to My Watchlist
5.26%
!
$14.01

Ann: 2023 Annual Report to shareholders, page-179
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$14.01 |
Change
0.700(5.26%) |
Mkt cap ! $1.730B |
Open | High | Low | Value | Volume |
$13.50 | $14.04 | $12.96 | $4.075M | 299.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 109 | $14.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$14.01 | 41 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
5 | 122 | 13.980 |
3 | 98 | 13.970 |
3 | 353 | 13.960 |
4 | 552 | 13.950 |
4 | 517 | 13.940 |
Price($) | Vol. | No. |
---|---|---|
14.000 | 13977 | 13 |
14.010 | 333 | 2 |
14.020 | 1151 | 4 |
14.030 | 981 | 4 |
14.040 | 1222 | 4 |
Last trade - 11.54am 27/06/2025 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
PTX
PRESCIENT THERAPEUTICS LIMITED
James McDonnell, CEO
James McDonnell
CEO
Previous Video
Next Video
SPONSORED BY The Market Online